The Gut-lung Axis in Chronic Obstructive Pulmonary Disease

• Conditions: Immunity, Mucosal; Pulmonary Disease, Chronic Obstructive; Metabolism; Microbiota

• Registration Number: NCT03236480
• Lead Sponsor: Peking University People's Hospital

Brief Summary

Patients with chronic obstructive pulmonary disease (COPD) are 2-3 times more likely to occur together with chronic gastrointestinal tract (GIT) diseases, such as inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS). Similarly, despite many patients have no history of acute or chronic respiratory disease, up to 50% of IBD patients and 33% of IBS patients have pulmonary involvement, such as inflammation or impaired lung function. Increasing evidence indicated chronic gut and lung disease share key conceptual features with the disorder and dysregulation of the microbial ecosystem. However, the underlying mechanisms are not well understood.

Our study is aimed to elucidate the intimate relationship between the gastrointestinal tract and respiratory tract, and uncover the mechanisms by which the gut microbiota affects the immune responses in the lungs, and vice versa.

Detailed Description

Not available

Study Timeline

• Study Start: 2017-01-01
• Status Verified: 2017-07
• Study First Submitted: 2017-07-28
• Study First Submitted QC: 2017-07-28
• Last Update Submitted: 2017-07-28
• Study First Posted: 2017-08-02
• Last Update Posted: 2017-08-02
• Primary Completion: 2018-07-01
• Study Completion: 2019-01-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• admitted to hospital with an exacerbation of COPD;
• with no history of probiotics taken;
• the duration of antibiotics treatment before enrollment should be less than 72 hours.

Exclusion Criteria

• being immunocompromised, including history of glucocorticoid taken for more than 1 month, history of immunosuppressive therapy, history of human immunodeficiency virus (HIV) infection, solid tumor or hematological malignancy;
• history of long-term nursing home stays;
• history of recently hospitalized (<90 days).

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
all-cause mortality	patients will be followed for 3 months after their remission from hospital	all-cause death after the enrollment

Secondary Outcome Measures

Name	Time	Method
exacerbations	during the 3-month follow-up	exacerbations of COPD

Trial Locations

Locations (1)

Peking University People's Hospital; 🇨🇳 Beijing, Beijing, China